{"disease":{"id":"glaucoma-and-ocular-hypertension","name":"glaucoma and ocular hypertension"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04967989","title":"Clarifying the Optimal Application of SLT Therapy Trial","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":790,"lead_sponsor_name":"University of Pittsburgh","has_results":false},{"nct_id":"NCT03691649","title":"A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 3 Study","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":426,"lead_sponsor_name":"Santen Inc.","has_results":true},{"nct_id":"NCT05181046","title":"Evaluation of Nanodropper-mediated Microdrops vs. Standard Drops of 0.5% Timolol Maleate in Glaucoma Patients","phase":"NA","overall_status":"COMPLETED","enrollment_count":420,"lead_sponsor_name":"Nanodropper, Inc.","has_results":false},{"nct_id":"NCT03691662","title":"A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 4 Study","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":417,"lead_sponsor_name":"Santen Inc.","has_results":true},{"nct_id":"NCT03697811","title":"DE-117 Spectrum 5 Study","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":107,"lead_sponsor_name":"Santen Inc.","has_results":true},{"nct_id":"NCT03858894","title":"Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Once Daily and Twice Daily in Subjects With Primary Open-Angle Glaucoma SPECTRUM 6","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":98,"lead_sponsor_name":"Santen Inc.","has_results":true},{"nct_id":"NCT06689696","title":"24-hour Wear Performance and Safety Study of Smartlens miLens Contact Lens for IOP Monitoring","phase":"","overall_status":"COMPLETED","enrollment_count":86,"lead_sponsor_name":"Smartlens, Inc.","has_results":false},{"nct_id":"NCT03187418","title":"Treatment Outcomes of MicroPulse Trans-scleral Cyclophotocoagulation in Uncontrolled Glaucoma","phase":"NA","overall_status":"COMPLETED","enrollment_count":52,"lead_sponsor_name":"Centre hospitalier de l'Université de Montréal (CHUM)","has_results":true},{"nct_id":"NCT03927118","title":"Effect of Dexamethasone Implant on Optic Disc","phase":"","overall_status":"COMPLETED","enrollment_count":43,"lead_sponsor_name":"Bulent Ecevit University","has_results":false},{"nct_id":"NCT02371746","title":"Safety and Efficacy of ENV515 Travoprost Extended Release (XR) in Patients With Bilateral Ocular Hypertension or Primary Open Angle Glaucoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":41,"lead_sponsor_name":"Envisia Therapeutics","has_results":true},{"nct_id":"NCT04061044","title":"A Study to Evaluate the Long Term Safety of OTX-TP (Sustained Release Travoprost) Intracanalicular Insert","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Ocular Therapeutix, Inc.","has_results":false}],"total":11},"guidelines":[],"source":"Drug Landscape verified database"}